Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 8,10 M
EBIT 2017 -35,7 M
Net income 2017 -35,9 M
Debt 2017 -
Yield 2017 -
Sales 2018 5,00 M
EBIT 2018 -27,1 M
Net income 2018 -36,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 3,01x
Capi. / Sales2018 4,87x
Capitalization 24,3 M
More Financials
Company
Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections.Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics, currently being evaluated in ongoing Phase 2b SPIRITUS... 
More about the company
Surperformance© ratings of Biota Pharmaceuticals Inc
Trading Rating : - Investor Rating :
More Ratings
Latest news on BIOTA PHARMACEUTICALS INC
02/14 AVIRAGEN THERAPEUTICS (NASDAQ : AVIR) Files An 8-K Other Events
02/13 Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial..
02/06 AVIRAGEN THERAPEUTICS, INC. : Management's Discussion and Analysis of Financial ..
02/03 AVIRAGEN THERAPEUTICS (NASDAQ : AVIR) Files An 8-K Results of Operations and Fin..
02/03 AVIRAGEN THERAPEUTICS, INC. : Results of Operations and Financial Condition, Fin..
02/02 Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Resul..
02/02 AVIRAGEN THERAPEUTICS, INC. (NASDAQ : AVIR) Files An 8-K Other Events
02/02 AVIRAGEN THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (f..
02/02 AVIRAGEN THERAPEUTICS : Announces Top-Line Results from Phase 2a RSV Challenge S..
02/01 Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge ..
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 3
Average target price 4,17 $
Spread / Average Target 561%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Joseph M. Patti President, CEO & Executive Director
Russell H. Plumb Executive Chairman
Mark P. Colonnese Chief Financial Officer & Executive Vice President
John H. Vernachio Vice President-Preclinical Development
Geoffrey F. Cox Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BIOTA PHARMACEUTICALS ..24
AMGEN, INC.19.01%128 555
GILEAD SCIENCES, INC.-3.13%92 143
CELGENE CORPORATION3.21%91 979
REGENERON PHARMACEUTIC..-1.67%38 296
ACTELION LTD22.36%28 792
More Results